---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-019338"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2024-02-23T23:59:59+00:00"
generated_at: "2026-06-05T17:09:47.583838+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Reneo Pharma to cut ~20% workforce, expects $1.7M severance charges in Q1 2024

## Summary
- Second workforce reduction of approximately 20% to be completed by February 29, 2024.
- Estimated $1.7 million in cash severance and employee termination costs in Q1 2024.
- Follows prior reduction announced December 14, 2023 as part of cost-saving plan.
- Actual charges may differ due to assumptions and potential additional costs.

## SEC filing metadata
- accession: 0000950170-24-019338
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2024-02-23T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.05
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000095017024019338/0000950170-24-019338-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000095017024019338/rphm-20240220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-019338
- JSON: https://secwatch.observer/filing/0000950170-24-019338.json
- Plain text: https://secwatch.observer/filing/0000950170-24-019338.txt

## Key facts
- Restructurings & Charges
  OnKure Therapeutics, Inc. announced a restructuring with charges of approximately $1.7 million (approximately 20%).
  - Type: restructuring
  - Charge: approximately $1.7 million
  - Headcount: approximately 20%
  source text: the Company expects to complete a second workforce reduction of approximately 20% on February 29, 2024 (the “Second Reduction”). In connection with the Second Reduction, the Company estimates that it will incur charges of approximately $1.7 million associated with cash severance payments and other employee termination-related costs in the first quarter of 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000095017024019338/0000950170-24-019338-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.